Skip to main navigation
close search window
CING | Nasdaq Listed
Header Menu
Company
About Cingulate®
Senior Management
Board of Directors
Scientific Advisors
Pipeline
Pipeline Overview
ADHD Patient Experience
Patient Experience
Treatments
Cingulate® Technology
Publications
CTx-1301: ADHD
CTx-1302: ADHD
CTX-2103: Anxiety
Partners
Investors
Webcasts & Presentations
Corporate Governance
Financials & Filings
SEC Filings
Analyst Coverage
Stock Information
Stock Quote & Chart
Historic Price Lookup
Investment Calculator
IR Resources
Investor FAQs
Email Alerts
Contact IR
Careers
Press Releases
Cingulate In the News
Connect With Us
Header Social
Twitter
LinkedIn
Facebook
Header Menu
Company
About Cingulate®
Senior Management
Board of Directors
Scientific Advisors
Pipeline
Pipeline Overview
ADHD Patient Experience
Patient Experience
Treatments
Cingulate® Technology
Publications
CTx-1301: ADHD
CTx-1302: ADHD
CTX-2103: Anxiety
Partners
Investors
Webcasts & Presentations
Corporate Governance
Financials & Filings
SEC Filings
Analyst Coverage
Stock Information
Stock Quote & Chart
Historic Price Lookup
Investment Calculator
IR Resources
Investor FAQs
Email Alerts
Contact IR
Careers
Press Releases
Cingulate In the News
Connect With Us
back to top
close search window
Search:
search submit button
Event Details
03 Oct 2024
Cingulate Initiates Final Study for Lead ADHD Asset
Click here for webcast
